A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

NCT02890069 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

298

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

Interventions

BIOLOGICAL: PDR001
DRUG: LCL161
DRUG: Everolimus
DRUG: Panobinostat
DRUG: QBM076
DRUG: HDM201

Sponsor

Novartis Pharmaceuticals